for EPILEPTIC, COGNITIVE
AND MOVEMENT DISORDERS
At SynapCell, our mission is to identify and qualify the therapeutic potential of your molecules. We reveal this potential, using EEG markers of CNS pathologies, for which we have established relevant standards.
You will be able to compare your molecule to the ones on the market and demonstrate its superiority.
An epileptic disorder is a chronic neurological condition characterized by recurrent epileptic seizures. Epileptic seizures are characterized by a hypersynchrony and hyperexcitability of one, or several, neural networks, leading to the appearance of spontaneous epileptiform events, recorded by EEG (spikes, discharges etc…). These events can be used as translational EEG biomarkers for drug discovery.
Markers: Spikes, Hippocampal Paroxysmal Discharges (HPD), Spike and wave discharge (SWD)
Programs: Lead selection (screening of small libraries of compounds), lead validation (dose-response effect, pharmacokinetic), disease modifying therapeutic potential, antiepileptogenic effect, rodent model phenotyping, derisking (pro-epileptic effect)
Cognitive disorders involve disturbances in information processing associated with cognitive impairment and/or progressive cognitive decline. These disorders can be studied using translational EEG biomarkers and can be accurately targeted for drug discovery.
Markers: ERPs, EROs, MMN, Gating, Multisite Coherence
Programs: Lead selection (screening of small libraries of compounds), lead validation (dose-response effect, pharmacokinetic), rodent model phenotyping
Movement disorders are a group of diseases and syndromes affecting a patient’s ability to produce and control movement of their body parts. These disorders represent a class of neurological conditions affecting the overall quality, speed and fluency of movement. Several movement alterations correlate with modifications to EEG activities. For example, in Parkinson’s disease, antikinetic and prokinetic oscillatory activities in the beta and gamma frequency bands are prominent. These activities can therefore be used as surrogate EEG biomarkers for drug discovery.
Markers: beta and gamma oscillations, Multisite coherence
Programs: Lead selection (screening of small libraries of compounds), lead validation (dose-response effect, pharmacokinetic), disease modifying therapeutic potential, rodent model phenotyping